Mineralys Therapeutics, Inc.MLYSNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank0
Studio
Year-over-Year Change

Year-over-year research & development expense growth

Percentile
P0
Near historical low
vs 3Y Ago
-0.8x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
PeriodValue
Q4 2025-22.41%
Q3 2025-17.84%
Q2 20251.05%
Q1 2025-15.01%
Q4 2024-17.44%
Q3 202437.46%
Q2 202427.70%
Q1 202429.85%
Q4 20235.27%
Q3 202389.32%
Q2 2023-3.33%
Q1 202357.24%
Q4 202229.03%
Q3 20228.29%
Q2 2022-17.45%
Q1 20222.45%
Q4 20210.00%